|
Information For:
|
Galantamine Tablets: Notice of Intent to Revise (Reposted)
In accordance with the Rules and Procedures of the Council of Experts, the Biopharmaceutics Expert Committee intends to revise the Galantamine Tablets monograph by adding another Dissolution test with a concomitant labeling requirement. The revisions to the Monograph will be made official in the near future as a Proposed Interim Revision Announcement. In the absence of any adverse comments, the revision will be published as final in Pharmacopeial Forum. The initial Notice of Intent to Revise for the Galantamine Tablets Monograph originally included revisions to impurities limits by the Monograph Development–Psychiatrics and Psychoactives Expert Committee. These changes were approved and published as an Interim Revision Announcement in PF 35(2) [Mar.–Apr. 2009]. See the original posting for Galantamine Tablets (posted 01–Aug–2008) in the Retired Compendial Notices section for more information. Should you have any questions please contact Margareth Marques, Ph.D., (301–816–8106 or ). What's NewPF 35(6) Errata (10/30/09) New official Text for October: 15 Revisions Bulletins (10/30/09) PF 35(6), November-December 2009: Highlights and Stimuli Articles (10/23/09) Admission Criteria and Safety Classification for Dietary Supplements Guideline (10/22/09) Elemental Impurities Hot Topics information updated (10/13/09) General Chapter <1151> Pharmaceutical Dosage Forms (10/06/09) Heparin Hot Topics information updated (10/02/09) New Official Text for September (09/29/09) Pending Standards for the month of September (09/25/09) PF 35(5) IRAs and Errata (08/31/09)
Related Resources |
||||||||||||||||||||||||||||
Copyright © 2009 The United States Pharmacopeial Convention
|
|||||||||||||||||||||||||||||